RevolKa launched a drug discovery program for rare diseases

Tokyo Japan- Jul 30, 2024. RevolKa Ltd. (Norio Hamamatsu, CEO) has initiated a drug discovery program for rare diseases in collaboration with Fukuoka Center for Disease Control and Prevention (F-CDC: Wataru Toriumi, DVM) and BioSafety Research Center Inc. (BSRC: Kenji Fukunaga, President and CEO), a subsidiary of Transgenic Inc. (Kenji Fukunaga, President and CEO). This team will conduct nonclinical pharmacology studies to validate RevolKa’s innovative drug candidates created by the game-changing AI-powered protein engineering technology called aiProtein®. Fukuoka Bio-Community, of which F-CDC and Transgenic Inc. are members, will also assist this collaboration. RevolKa will leverage this drug discovery program to build the company’s value and growth.